139 related articles for article (PubMed ID: 36220070)
21. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
Kitajima S; Ivanova E; Guo S; Yoshida R; Campisi M; Sundararaman SK; Tange S; Mitsuishi Y; Thai TC; Masuda S; Piel BP; Sholl LM; Kirschmeier PT; Paweletz CP; Watanabe H; Yajima M; Barbie DA
Cancer Discov; 2019 Jan; 9(1):34-45. PubMed ID: 30297358
[No Abstract] [Full Text] [Related]
22. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
23. Probing Mutant KRAS, STK11, KEAP1 in NSCLC.
Cancer Discov; 2022 Oct; 12(10):2226. PubMed ID: 35997519
[TBL] [Abstract][Full Text] [Related]
24. Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers.
Della Corte CM; Byers LA
Cancer Discov; 2019 Jan; 9(1):16-18. PubMed ID: 30626603
[TBL] [Abstract][Full Text] [Related]
25. MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer.
Kitajima S; Tani T; Springer BF; Campisi M; Osaki T; Haratani K; Chen M; Knelson EH; Mahadevan NR; Ritter J; Yoshida R; Köhler J; Ogino A; Nozawa RS; Sundararaman SK; Thai TC; Homme M; Piel B; Kivlehan S; Obua BN; Purcell C; Yajima M; Barbie TU; Lizotte PH; Jänne PA; Paweletz CP; Gokhale PC; Barbie DA
Cancer Cell; 2022 Oct; 40(10):1128-1144.e8. PubMed ID: 36150391
[TBL] [Abstract][Full Text] [Related]
26. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
27. Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.
Momcilovic M; McMickle R; Abt E; Seki A; Simko SA; Magyar C; Stout DB; Fishbein MC; Walser TC; Dubinett SM; Shackelford DB
Cancer Res; 2015 Nov; 75(22):4910-22. PubMed ID: 26574479
[TBL] [Abstract][Full Text] [Related]
28. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
Schabath MB; Welsh EA; Fulp WJ; Chen L; Teer JK; Thompson ZJ; Engel BE; Xie M; Berglund AE; Creelan BC; Antonia SJ; Gray JE; Eschrich SA; Chen DT; Cress WD; Haura EB; Beg AA
Oncogene; 2016 Jun; 35(24):3209-16. PubMed ID: 26477306
[TBL] [Abstract][Full Text] [Related]
29. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
[TBL] [Abstract][Full Text] [Related]
30. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
[TBL] [Abstract][Full Text] [Related]
31. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Scheffler M; Ihle MA; Hein R; Merkelbach-Bruse S; Scheel AH; Siemanowski J; Brägelmann J; Kron A; Abedpour N; Ueckeroth F; Schüller M; Koleczko S; Michels S; Fassunke J; Pasternack H; Heydt C; Serke M; Fischer R; Schulte W; Gerigk U; Nogova L; Ko YD; Abdulla DSY; Riedel R; Kambartel KO; Lorenz J; Sauerland I; Randerath W; Kaminsky B; Hagmeyer L; Grohé C; Eisert A; Frank R; Gogl L; Schaepers C; Holzem A; Hellmich M; Thomas RK; Peifer M; Sos ML; Büttner R; Wolf J
J Thorac Oncol; 2019 Apr; 14(4):606-616. PubMed ID: 30605727
[TBL] [Abstract][Full Text] [Related]
32. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
Ndembe G; Intini I; Moro M; Grasselli C; Panfili A; Panini N; Bleve A; Occhipinti M; Borzi C; Garassino MC; Marabese M; Canesi S; Scanziani E; Sozzi G; Broggini M; Ganzinelli M
J Exp Clin Cancer Res; 2024 Jan; 43(1):6. PubMed ID: 38163906
[TBL] [Abstract][Full Text] [Related]
33. Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.
Kitajima S; Asahina H; Chen T; Guo S; Quiceno LG; Cavanaugh JD; Merlino AA; Tange S; Terai H; Kim JW; Wang X; Zhou S; Xu M; Wang S; Zhu Z; Thai TC; Takahashi C; Wang Y; Neve R; Stinson S; Tamayo P; Watanabe H; Kirschmeier PT; Wong KK; Barbie DA
Cancer Cell; 2018 Sep; 34(3):439-452.e6. PubMed ID: 30205046
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
[TBL] [Abstract][Full Text] [Related]
35. Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient.
Domingues I; Cedres S; Callejo A; Vivancos A; Martinez-Marti A; Felip E
Pulmonology; 2020; 26(1):49-50. PubMed ID: 31401029
[No Abstract] [Full Text] [Related]
36. AXL targeting restores PD-1 blockade sensitivity of
Li H; Liu Z; Liu L; Zhang H; Han C; Girard L; Park H; Zhang A; Dong C; Ye J; Rayford A; Peyton M; Li X; Avila K; Cao X; Hu S; Alam MM; Akbay EA; Solis LM; Behrens C; Hernandez-Ruiz S; Lu W; Wistuba I; Heymach JV; Chisamore M; Micklem D; Gabra H; Gausdal G; Lorens JB; Li B; Fu YX; Minna JD; Brekken RA
Cell Rep Med; 2022 Mar; 3(3):100554. PubMed ID: 35492873
[TBL] [Abstract][Full Text] [Related]
37. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
[TBL] [Abstract][Full Text] [Related]
38. Targeting PGM3 as a Novel Therapeutic Strategy in
Lee H; Cai F; Kelekar N; Velupally NK; Kim J
Cells; 2022 Jan; 11(1):. PubMed ID: 35011738
[TBL] [Abstract][Full Text] [Related]
39. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.
Torralvo J; Friedlaender A; Achard V; Addeo A
Cancer Genomics Proteomics; 2019; 16(6):577-582. PubMed ID: 31659111
[TBL] [Abstract][Full Text] [Related]
40. Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional
Pore N; Wu S; Standifer N; Jure-Kunkel M; de Los Reyes M; Shrestha Y; Halpin R; Rothstein R; Mulgrew K; Blackmore S; Martin P; Meekin J; Griffin M; Bisha I; Proia TA; Miragaia RJ; Herbst R; Gupta A; Abdullah SE; Raja R; Frigault MM; Barrett JC; Dennis PA; Ascierto ML; Oberst MD
Cancer Discov; 2021 Nov; 11(11):2828-2845. PubMed ID: 34230008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]